5sam: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
New page: '''Unreleased structure''' The entry 5sam is ON HOLD until Paper Publication Authors: Wollenhaupt, J., Metz, A., Messini, N., Barthel, T., Klebe, G., Weiss, M.S. Description: Endothiap...
 
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Unreleased structure'''


The entry 5sam is ON HOLD  until Paper Publication
==Endothiapepsin in complex with compound FU5-3==
<StructureSection load='5sam' size='340' side='right'caption='[[5sam]], [[Resolution|resolution]] 1.20&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5SAM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5SAM FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.2&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=ZS7:3-amino-1H-isoindol-1-one'>ZS7</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5sam FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5sam OCA], [https://pdbe.org/5sam PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5sam RCSB], [https://www.ebi.ac.uk/pdbsum/5sam PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5sam ProSAT]</span></td></tr>
</table>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
In recent years, crystallographic fragment screening has matured into an almost routine experiment at several modern synchrotron sites. The hits of the screening experiment, i.e. small molecules or fragments binding to the target protein, are revealed along with their 3D structural information. Therefore, they can serve as useful starting points for further structure-based hit-to-lead development. However, the progression of fragment hits to tool compounds or even leads is often hampered by a lack of chemical feasibility. As an attractive alternative, compound analogs that embed the fragment hit structurally may be obtained from commercial catalogs. Here, a workflow is reported based on filtering and assessing such potential follow-up compounds by template docking. This means that the crystallographic binding pose was integrated into the docking calculations as a central starting parameter. Subsequently, the candidates are scored on their interactions within the binding pocket. In an initial proof-of-concept study using five starting fragments known to bind to the aspartic protease endothiapepsin, 28 follow-up compounds were selected using the designed workflow and their binding was assessed by crystallography. Ten of these compounds bound to the active site and five of them showed significantly increased affinity in isothermal titration calorimetry of up to single-digit micromolar affinity. Taken together, this strategy is capable of efficiently evolving the initial fragment hits without major synthesis efforts and with full control by X-ray crystallography.


Authors: Wollenhaupt, J., Metz, A., Messini, N., Barthel, T., Klebe, G., Weiss, M.S.
Frag4Lead: growing crystallographic fragment hits by catalog using fragment-guided template docking.,Metz A, Wollenhaupt J, Glockner S, Messini N, Huber S, Barthel T, Merabet A, Gerber HD, Heine A, Klebe G, Weiss MS Acta Crystallogr D Struct Biol. 2021 Sep 1;77(Pt 9):1168-1182. doi:, 10.1107/S2059798321008196. Epub 2021 Aug 23. PMID:34473087<ref>PMID:34473087</ref>


Description: Endothiapepsin in complex with compound FU5-3
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
[[Category: Unreleased Structures]]
</div>
[[Category: Metz, A]]
<div class="pdbe-citations 5sam" style="background-color:#fffaf0;"></div>
[[Category: Messini, N]]
 
[[Category: Weiss, M.S]]
==See Also==
[[Category: Klebe, G]]
*[[Pepsin|Pepsin]]
[[Category: Wollenhaupt, J]]
== References ==
[[Category: Barthel, T]]
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Barthel T]]
[[Category: Klebe G]]
[[Category: Messini N]]
[[Category: Metz A]]
[[Category: Weiss MS]]
[[Category: Wollenhaupt J]]

Latest revision as of 12:23, 23 October 2024

Endothiapepsin in complex with compound FU5-3Endothiapepsin in complex with compound FU5-3

Structural highlights

Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 1.2Å
Ligands:, ,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Publication Abstract from PubMed

In recent years, crystallographic fragment screening has matured into an almost routine experiment at several modern synchrotron sites. The hits of the screening experiment, i.e. small molecules or fragments binding to the target protein, are revealed along with their 3D structural information. Therefore, they can serve as useful starting points for further structure-based hit-to-lead development. However, the progression of fragment hits to tool compounds or even leads is often hampered by a lack of chemical feasibility. As an attractive alternative, compound analogs that embed the fragment hit structurally may be obtained from commercial catalogs. Here, a workflow is reported based on filtering and assessing such potential follow-up compounds by template docking. This means that the crystallographic binding pose was integrated into the docking calculations as a central starting parameter. Subsequently, the candidates are scored on their interactions within the binding pocket. In an initial proof-of-concept study using five starting fragments known to bind to the aspartic protease endothiapepsin, 28 follow-up compounds were selected using the designed workflow and their binding was assessed by crystallography. Ten of these compounds bound to the active site and five of them showed significantly increased affinity in isothermal titration calorimetry of up to single-digit micromolar affinity. Taken together, this strategy is capable of efficiently evolving the initial fragment hits without major synthesis efforts and with full control by X-ray crystallography.

Frag4Lead: growing crystallographic fragment hits by catalog using fragment-guided template docking.,Metz A, Wollenhaupt J, Glockner S, Messini N, Huber S, Barthel T, Merabet A, Gerber HD, Heine A, Klebe G, Weiss MS Acta Crystallogr D Struct Biol. 2021 Sep 1;77(Pt 9):1168-1182. doi:, 10.1107/S2059798321008196. Epub 2021 Aug 23. PMID:34473087[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Metz A, Wollenhaupt J, Glöckner S, Messini N, Huber S, Barthel T, Merabet A, Gerber HD, Heine A, Klebe G, Weiss MS. Frag4Lead: growing crystallographic fragment hits by catalog using fragment-guided template docking. Acta Crystallogr D Struct Biol. 2021 Sep 1;77(Pt 9):1168-1182. PMID:34473087 doi:10.1107/S2059798321008196

5sam, resolution 1.20Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA